Company Overview - Longevity Health Holdings, Inc. focuses on human longevity and healthy aging, recently announcing a merger with True Health Inc., a key player in the plasma collection industry [1][2] - True Health operates under the THPlasma brand and has established a growing network of plasma collection centers in the Northeast United States [7] Merger Details - The merger is an all-stock transaction, with the combined company expected to continue trading on Nasdaq under the symbol "XAGE" [1] - The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare, enhancing its capabilities in plasma-derived growth factors and exosomes [2] Industry Context - The United States supplies over 60% of the world's plasma but faces a shortfall in plasma and plasma-derived therapeutics, creating a significant market opportunity for THPlasma [3] - THPlasma is addressing this shortfall with a rapidly expanding footprint of plasma collection centers [3] Financial Highlights - THPlasma has guaranteed sales offtake agreements for up to $100 million annually and achieved cash profitability in FY2024 [8] - Projected FY2025 revenue for THPlasma is estimated at $10 million, with EBITDA of $2 million and net income of $1 million, while FY2026 estimates show revenue growth to $32 million, EBITDA of $7 million, and net income of $4 million [8] Strategic Vision - The merger is expected to unlock access to public markets and future M&A opportunities, with both companies' leadership expressing optimism about growth and value creation [6][8] - Longevity aims to drive further growth in THPlasma through both acquisitions and organic growth strategies [6]

Core Viewpoint - Longevity Health Holdings, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent upon meeting initial listing rules following its proposed merger with 20/20 BioLabs by September 2, 2025 [1][3]. Company Overview - Longevity Health Holdings focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][4]. - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [4]. Merger Details - The proposed merger with 20/20 BioLabs includes a strategic plan to effect a 1-for-30 reverse stock split to meet Nasdaq's listing requirements [2]. - The S-4 registration statement for the merger was filed on May 8, 2025, and the reverse stock split was executed on May 12, 2025 [2]. 20/20 BioLabs Overview - 20/20 BioLabs specializes in developing innovative laboratory tests for early detection and management of chronic disease risks, including a multi-cancer early detection blood test available in the U.S. [5]. - The company plans to introduce a new blood test for monitoring chronic inflammation, which is linked to several leading causes of death in America [5].

Core Insights - Longevity Health Holdings, Inc. (XAGE) focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [2] - The company announced a merger agreement with 20/20 BioLabs, which will continue as a wholly owned subsidiary post-merger [4] Business Updates - 20/20 develops laboratory tests for early detection and management of chronic disease risk, including a multi-cancer early detection blood test and a new blood test for monitoring chronic inflammation [1][4] - XAGE reported Q1 sales of approximately $663,000, an 8% increase year-over-year, while 20/20 reported sales of approximately $562,000, a 15% increase year-over-year [4] - A reverse stock split of 1 for 30 was completed on May 12, 2025, with trading at the adjusted price starting on May 14, 2025 [4] Product Launches - XAGE plans to launch a medicated cleanser for use in physicians' offices and MedSpas, targeting 20/20's customer base [4] - 20/20 is set to launch a lab test measuring inflammatory biomarkers, which will also be marketed to XAGE's customer base [4] - An initiative with Giant Food will offer 20/20's multi-cancer test in select stores, with potential expansion to include tests for biomarkers linked to pro-inflammatory foods [4] Financial Considerations - XAGE is evaluating options for additional financing and anticipates announcing a primary investment in Q2 2025 [4]